<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918330</url>
  </required_header>
  <id_info>
    <org_study_id>SpIM</org_study_id>
    <nct_id>NCT03918330</nct_id>
  </id_info>
  <brief_title>Spatial Analysis of the Intestinal Microbiota in Healthy Subjects</brief_title>
  <official_title>Spatial Analysis of the Intestinal Microbiota in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research on the human intestinal microbiota is common as there is rising evidence of its&#xD;
      influence on host physiology and several diseases. Predominantly, it has been based on&#xD;
      analyses of faecal samples because of their easy sampling. A minority of studies investigated&#xD;
      the gut microbiota using mucosal samples. Not much is known about the spatial differences in&#xD;
      microbiota composition along the large bowel. The spatial differences of the gut microbiota&#xD;
      without preparation of the bowel have not been analysed yet. Furthermore, the composition of&#xD;
      the microbiota of the luminal gut content has not been analysed yet.&#xD;
&#xD;
      This study aims to gain knowledge of the microbial composition of luminal and mucosal samples&#xD;
      at different segments of the lower gastrointestinal tract: ileum, caecum, ascending colon,&#xD;
      transverse colon, descending colon, sigmoid colon and rectum, as well as of rectal swabs and&#xD;
      faecal samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to evaluate complete colonoscopies from 10 healthy subjects. This study&#xD;
      is used as a first explorative study of how the human gut microbiota is distributed along the&#xD;
      lower gastrointestinal tract. No comparable studies in an uncleansed bowel have been&#xD;
      performed so far. The number of subjects is based on other studies investigating the&#xD;
      microbial composition of mucosal- and faecal-associated microbiota in which a sample size of&#xD;
      10 was enough to detect a difference. An equal number of men and women will be recruited.&#xD;
      Drop-outs will be replaced.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in the composition of the microbiota in luminal and mucosal samples along the large intestine Composition of the microbiota in luminal as well as mucosal samples</measure>
    <time_frame>1 day</time_frame>
    <description>16S rRNA-based next generation sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbial composition of rectal and faecal microbiota</measure>
    <time_frame>1 day</time_frame>
    <description>16S rRNA-based next generation sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile in faecal samples along the intestinal tract</measure>
    <time_frame>1 day</time_frame>
    <description>metabolomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression of transporters for bacterial products in mucosal biopsies along the colon</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Subjects</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bacterial DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        10 healthy volunteers will be recruited via local advertisements.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Age: 18-65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known organic gastrointestinal disease (e.g. inflammatory bowel disease, irritable&#xD;
             bowel syndrome, chronic diarrhoea or constipation)&#xD;
&#xD;
          2. History of or present gastrointestinal malignancy or polyposis&#xD;
&#xD;
          3. Recent (gastrointestinal) infection (within last 6 months)&#xD;
&#xD;
          4. History of major gastrointestinal surgery (e.g. gastric bypass)&#xD;
&#xD;
          5. Eosinophilic disorders of the gastrointestinal tract&#xD;
&#xD;
          6. Current communicable disease (e.g. upper respiratory tract infection)&#xD;
&#xD;
          7. Malignant disease and/or patients who are receiving systemic anti-neoplastic agents&#xD;
&#xD;
          8. Psychiatric diseases (e.g. dementia, depression, schizophrenia, autism, Asperger&#xD;
             Syndrome) or other incapacity for adequate cooperation&#xD;
&#xD;
          9. Chronic neurological/neurodegenerative diseases (e.g. Parkinson's disease, multiple&#xD;
             sclerosis)&#xD;
&#xD;
         10. Autoimmune disease and/or patients receiving immunosuppressive medications&#xD;
&#xD;
         11. Major relevant allergies (e.g. food allergy, multiple allergies)&#xD;
&#xD;
         12. Chronic pain syndromes (e.g. fibromyalgia)&#xD;
&#xD;
         13. Chronic fatigue syndrome&#xD;
&#xD;
         14. Obesity (body mass index&gt;30) or metabolic syndrome&#xD;
&#xD;
         15. Antimicrobial treatment or prophylaxis within the last 3 months&#xD;
&#xD;
         16. Other chronic use of drugs that may affect the microbiome, e.g. proton pump inhibitors&#xD;
&#xD;
         17. Females who are pregnant or breast-feeding&#xD;
&#xD;
         18. Known clinically significant abnormal laboratory values&#xD;
&#xD;
         19. Abuse of alcohol or drugs&#xD;
&#xD;
         20. Probiotic intake within the last 6 weeks&#xD;
&#xD;
         21. Bowel cleansing within the last 6 months&#xD;
&#xD;
         22. Any clinically significant disease/condition which in the investigator's opinion could&#xD;
             interfere with the results of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Brummer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Örebro County, Örebro University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Örebro university</name>
      <address>
        <city>Örebro</city>
        <state>Örebro County</state>
        <zip>70182</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

